Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"The Division of Cancer Treatment and Diagnosis","sponsor":"Sapphire Biotech","pharmaFlowCategory":"D","amount":"$0.4 million","upfrontCash":"Undisclosed","newsHeadline":"Sapphire Biotech Awarded Prestigious Phase I Small Business Innovation Research Grant by National Cancer Institute","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"The Division of Cancer Treatment and Diagnosis","sponsor":"Zenith Epigenetics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Zenith Epigenetics Announces Collaboration with NCI in Developing ZEN-3694 for Multiple Oncology Indications","therapeuticArea":"Oncology","highestDevelopmentStatus":"Undisclosed","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Undisclosed"},{"orgOrder":0,"company":"The Division of Cancer Treatment and Diagnosis","sponsor":"TumorGen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"TumorGen Receives $390K NCI Grant to Counter Metastasis","therapeuticArea":"Oncology","highestDevelopmentStatus":"Discovery Platform","country":"U.S.A","productType":"Undisclosed","productStatus":"Undisclosed","date":"August 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Discovery Platform"}]

    Find Clinical Drug Pipeline Developments & Deals by The Division of Cancer Treatment and Diagnosis

    Menu

    The Division of Cancer Treatment and Diagnosis

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              The Division of Cancer Treatment and Diagnosis

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              TumorGen Receives $390K NCI Grant to Counter Metastasis

              Details:

              With this funding, the company will test the new technology in lung cancer patients, capturing metastatic cancer cell clusters (MCCCs) in their blood.

              Lead Product(s): Undisclosed

              Therapeutic Area: Oncology Product Name: Undisclosed

              Highest Development Status: Discovery Platform Product Type: Undisclosed

              Recipient: TumorGen

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Funding August 26, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              The Division of Cancer Treatment and Diagnosis

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Zenith Epigenetics Announces Collaboration with NCI in Developing ZEN-3694 for Multiple Oncology Indications

              Details:

              First clinical Study to Combine ZEN-3694 with BMS’s immune checkpoint inhibitors nivolumab and ipilimumab for treatment of ovarian cancer.

              Lead Product(s): ZEN-3694,Nivolumab,Ipilimumab

              Therapeutic Area: Oncology Product Name: ZEN-3694

              Highest Development Status: Undisclosed Product Type: Small molecule

              Recipient: Zenith Epigenetics

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement October 05, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              The Division of Cancer Treatment and Diagnosis

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Sapphire Biotech Awarded Prestigious Phase I Small Business Innovation Research Grant by National Cancer Institute

              Details:

              The grant will support the continued development of novel small molecules that inhibit the enzymatic activity of Quiescin Sulfhydryl Oxidase I (“QSOX1”) based on a lead compound. QSOX1 is a tumor-derived enzyme that is important for cancer growth, invasion and metastasis.

              Lead Product(s): SPX-1009

              Therapeutic Area: Oncology Product Name: SPX-1009

              Highest Development Status: Preclinical Product Type: Small molecule

              Recipient: Sapphire Biotech

              Deal Size: $0.4 million Upfront Cash: Undisclosed

              Deal Type: Funding August 11, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              Temad- We think of world-class quality.
              Post Enquiry
              POST ENQUIRY